Last reviewed · How we verify
echinacea/sage — Competitive Intelligence Brief
phase 3
Infectious Diseases
Small molecule
Live · refreshed every 30 min
Target snapshot
echinacea/sage (echinacea/sage) — A. Vogel AG. Echinacea/sage combination acts to reduce symptoms of sore throat and upper respiratory tract infections through its anti-inflammatory and antimicrobial properties.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| echinacea/sage TARGET | echinacea/sage | A. Vogel AG | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- echinacea/sage CI watch — RSS
- echinacea/sage CI watch — Atom
- echinacea/sage CI watch — JSON
- echinacea/sage alone — RSS
Cite this brief
Drug Landscape (2026). echinacea/sage — Competitive Intelligence Brief. https://druglandscape.com/ci/echinacea-sage. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing